A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 (NCT06770933)
A Phase II, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy OF Non-Proliferative Type (NPDR)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Who can join: Review the eligibility criteria below.
Location: Retina-Vitreous Associates Medical Group — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Retina-Vitreous Associates Medical Group — Beverly Hills, California
- Stanford Byers Eye Institute — Palo Alto, California
- California Retina Consultants- Santa Barbara — Santa Barbara, California
- Florida Retina Institute - Jacksonville Southside — Jacksonville, Florida
- Retina Associates — Elmhurst, Illinois
- Cumberland Valley Retina Consultants — Hagerstown, Maryland
- Erie Retina Research — Erie, Pennsylvania
- Piedmont Eye Center — Lynchburg, Virginia
- Eye Clinic Albury Wodonga — Albury, New South Wales
- Retina And Eye Consultants Hurstville — Hurstville, New South Wales
- Marsden Eye Specialists — Parramatta, New South Wales
- Sydney Eye Hospital — Sydney, New South Wales
- Sydney Retina Clinic — Sydney, New South Wales
- Sydney West Retina — Westmead, New South Wales
- University of the Sunshine Coast Clinical Trials (Birtinya) — Birtinya, Queensland
- Royal Adelaide Hospital — Adelaide, South Australia
- Prince of Wales Hospital The Chinese University of Hong Kong — Shatin,
- HKU Eye Centre — Wong Chuk Hang,
- University Malaya Medical Centre — Petaling Jaya, Kuala Lumpur Federal Territory of Kuala Lumpur
- Hospital Pulau Pinang — George Town, Pulau Pinang
- Hospital Shah Alam — Shah Alam, Selangor
- Hospital Al-sultan Abdullah Uitm — Sungai Buloh, Selangor
- Hospital Selayang — Selayang Baru Utara,
- Seoul National University Bundang Hospital — Seongnam-si,
- Asan Medical Center — Seoul,
📞 Contact the Study Coordinator
Phone: +44 7450953382
Email: steffy.george@vantage-biosciences.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetic Retinopathy
- Vascular Reparative Mechanism in Diabetes — Birmingham, Alabama
- OCT Biomarkers for Diabetic Retinopathy — Portland, Oregon
- WF and PR OCTA in Diabetic Retinopathy — Portland, Oregon
- Camera Qualification Study — Norco, California
- A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy — Phoenix, Arizona
- Implementation of Teleophthalmology in Urban Health Systems Study — Madison, Wisconsin
Explore by condition: All Diabetic Retinopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.